Bahareh (Spring) Behrouz, PhD, is the CEO of Vincere Biosciences Inc, focused on developing therapeutics targeting mitochondrial pathways. She is also CEO of NeuroInitiative, LLC, a computational biology company she co-founded in 2014, which develops simulations of disease using their patented software platform. The focus of her research is the elucidation of converging pathways that contribute to the pathogenesis of Parkinson's disease (PD).
Dr. Behrouz received her graduate training at Michigan State University in the laboratory of Dr. John Goudreau and studied differential susceptibility of dopaminergic neuron subtypes in models of PD. She completed her post-doctoral training in the laboratory of Dr. Matthew Farrer at the Mayo Clinic in Jacksonville, where she primarily focused on in vivo and primary culture models of LRRK2-mediated pathogenesis.